Investigational Drug Details
| Drug ID: | D409 |
| Drug Name: | Intraconazole |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 84625-61-6 |
| Repositioning for NAFLD: | No |
| SMILES: | VHVPQPYKVGDNFY-WGEGMAFPNA-N |
| InChiKey: | O=C1N(N=CN1C2=CC=C(C=C2)N3CCN(C4=CC=C(OCC5OC(OC5)(C6=CC=C(Cl)C=C6Cl)CN7N=CN=C7)C=C4)CC3)C(C)CC |
| Molecular Weight: | 705.63 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | P450 inhibitor |
| Therapeutic Category: | Antimycotic drug |
| Clinical Trial Progress: | Phase 2 completed (NCT03421431 LAY SUMMARY: Non-alcoholic fatty liver disease is a chronic hepatic disease that can progress to non-alcoholic steatohepatitis (NASH), which is associated with an increased risk of cirrhosis and liver cancer. Results from this phase II study support continued development of EDP-305, an oral farnesoid X receptor agonist, for the treatment of patients with NASH.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0310 | NCT03213145 | Phase 1 | Completed | No Results Available | July 11, 2017 | November 6, 2017 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|